Sobi enters new credit facility and redeems SEK 800 M bond loan 2012/2017 prior to final maturity

Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com) (Sobi™) has a SEK 800
million bond loan with a final maturity on 27 June 2017 (the “Bond Loan”). The
Bond Loan has a floating rate coupon of STIBOR 3 months plus 5 per cent per
year. Sobi hereby irrevocably gives notice that it will redeem the Bond Loan on
27 June 2016 in advance of its final maturity.

To redeem the Bond Loan, Sobi has entered into a three year SEK 500 million term
and SEK 500 million revolving facilities agreement with Svenska Handelsbanken AB
(publ) and Danske Bank A/S, Danmark, Sverige Filial. Part of the facility will
be used, together with own funds, to redeem the Bond Loan on 27 June 2016 in
accordance with Clause 7.4 of the terms and conditions of the Bond Loan. Each
Bond will be redeemed at a redemption amount equal to 101 per cent of its
nominal amount together with accrued but unpaid interest.

Payment will be made to all who, in accordance with the terms and conditions of
the Bond Loan, are registered as “Bondholder” on 17 June 2016.

This notice of early redemption is irrevocable.

---

About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products across Europe, the Middle
East, North Africa and Russia for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on
NASDAQ Stockholm.

For more information please contact

Media relations         Investor relations
Oskar Bosson, Head of   Jörgen Winroth, Vice
Communications          President, Head of Investor
                        Relations
T: +46 70 410 71 80     T: +1 347-224-0819, +1 212
                        -579-0506, +46 8 697 2135
oskar.bosson@sobi.com   jorgen.winroth@sobi.com

The information set out in this press release is announced in accordance with
the Swedish Securities Market Act. The information was submitted for publication
on 27 May 2016 at 08:00 CET.